DAWN - CIK 0001845337
Day One Biopharmaceuticals, Inc. trades as DAWN and has a market capitalization of $2.22 B, making it the #2027 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $158.18M, up 20.6% from the prior year and net income of -$107.32B. This page tracks Day One Biopharmaceuticals, Inc. through 493 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-14 |
| 15-12G | - | 2026-05-04 |
| SCHEDULE 13D/A | - | 2026-04-27 |
| Insider trade | 4 | 2026-04-27 |
| Insider trade | 4 | 2026-04-23 |
| Insider trade | 4 | 2026-04-23 |
| Insider trade | 4 | 2026-04-23 |
The largest companies sharing Day One Biopharmaceuticals, Inc.'s SEC industry classification (pharmaceutical preparations).
Day One Biopharmaceuticals, Inc. (DAWN) has a market capitalization of $2.22 B as of 2026-06-10, ranking #2027 among US-listed companies.
Day One Biopharmaceuticals, Inc. reported revenue of $158.18M for fiscal year 2025, an increase of 20.6% year over year.
In its latest fiscal year Day One Biopharmaceuticals, Inc. reported a net loss of $107.32B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.